Literature DB >> 10086063

Current and future modalities for functional renal replacement.

G E Amiel1, A Atala.   

Abstract

Approximately 310,000 Americans suffer from end-stage renal disease, with more than 70,000 new cases reported each year. Advances in immunosuppressive therapy for transplanted patients, in addition to the refined care of patients who are dependent on dialysis, have led to an improved survival for patients with renal failure. Structural, molecular, and pharmacologic developments continue to enhance the efficacy and safety of dialysis in the future. In addition, progressive improvements in the past 2 decades in organ transplantation, a greater insight into the immunobiology of graft rejection, and better surgical and medical management have resulted in improved outcomes. Although renal xenotransplantation is still in its early stages of development, additional research is leading this technology forward. Recent successes in harvesting and expanding renal cells in vitro and the development of biologically active synthetic materials allow for the creation of three-dimensional functioning renal units, which, in the future, may be applied ex vivo or in vivo for partial or full replacement of kidney function.

Entities:  

Mesh:

Year:  1999        PMID: 10086063     DOI: 10.1016/s0094-0143(99)80019-6

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  9 in total

1.  Renal differentiation of amniotic fluid stem cells.

Authors:  L Perin; S Giuliani; D Jin; S Sedrakyan; G Carraro; R Habibian; D Warburton; A Atala; R E De Filippo
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

2.  Tissue engineered testicular prostheses with prolonged testosterone release.

Authors:  Atlantida M Raya-Rivera; Carlos Baez; Anthony Atala; James J Yoo
Journal:  World J Urol       Date:  2008-06-07       Impact factor: 4.226

3.  Erythropoietin producing cells for potential cell therapy.

Authors:  Tamer Aboushwareb; Fernanda Egydio; Lauren Straker; Kenneth Gyabaah; Anthony Atala; James J Yoo
Journal:  World J Urol       Date:  2008-07-08       Impact factor: 4.226

4.  Regenerative medicine strategies for treating neurogenic bladder.

Authors:  James J Yoo; Jennifer Olson; Anthony Atala; Bupwan Kim
Journal:  Int Neurourol J       Date:  2011-09-30       Impact factor: 2.835

5.  Tissue engineering: current strategies and future directions.

Authors:  Jennifer L Olson; Anthony Atala; James J Yoo
Journal:  Chonnam Med J       Date:  2011-04-26

Review 6.  Tissue engineering of the penis.

Authors:  Manish N Patel; Anthony Atala
Journal:  ScientificWorldJournal       Date:  2011-12-29

7.  Tissue engineering, stem cells, cloning, and parthenogenesis: new paradigms for therapy.

Authors:  Jason Hipp; Anthony Atala
Journal:  J Exp Clin Assist Reprod       Date:  2004-12-08

Review 8.  Tissue engineering in urology.

Authors:  A Atala
Journal:  Curr Urol Rep       Date:  2001-02       Impact factor: 2.862

9.  Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure.

Authors:  Steve J Hodges; Anthony Atala
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.